Article
作者: Dugel, Pravin ; Sivaprasad, Sobha ; Brucker, Alexander ; Jin, Xidong ; Berger, Brian ; Patel, Sunil ; Barranco, Jose Juan Escobar ; Figueira, João ; Silva, Rufino ; Habib, Maged ; Calvo, Pilar ; Bailey, Claire ; Hu, Allen ; Jhaveri, Chirag ; Boyer, David S. ; Ghanchi, Faruque ; Dong Nguyen, Quan ; Erke, Maja Gran ; Bandello, Francesco ; Kunimoto, Derek ; Donate Lopez, Juan ; Talks, James ; Giani, Andrea ; Pagliarini, Sergio ; Varano, Monica ; Menon, Geeta ; Maturi, Raj ; Sen, Harsha ; Rosen, Richard ; Androudi, Sofia ; Ehrlich, Michael S. ; Fawzi, Amani ; Weger, Martin ; Cunningham, Matthew ; Hahn, Paul ; Antoszyk, Andrew ; Manjunatha, Nonavinakere ; Ehlers, Justis P. ; Brown, David
AbstractObjectiveTo evaluate the safety and efficacy of BI 1467335 in patients with non-proliferative diabetic retinopathy (NPDR).MethodsROBIN is a Phase IIa, double-masked, randomised, placebo-controlled study (NCT03238963). Patients with NPDR and without centre-involved diabetic macular oedema were included; all had a best corrected visual acuity letter score of ≥70 Early Treatment Diabetic Retinopathy Study letters in the study eye at screening. Patients received oral BI 1467335 10 mg or placebo once daily for 12 weeks. Post-treatment follow-up was 12 weeks. The primary endpoint was the proportion of patients over the 24 weeks with ocular adverse events (AEs). Secondary endpoints were the proportion of patients with ≥2-step improvement from baseline in DRSS severity level at Week 12 and the proportion of patients with non-ocular AEs at 24 weeks.ResultsSeventy-nine patients entered the study (BI 1467335, n = 40; placebo, n = 39). The proportion of patients with ocular AEs over 24 weeks was greater in the BI 1467335 versus the placebo group (35.0% vs 23.1%, respectively). Treatment-related AEs were reported for similar numbers of patients in the placebo and BI 1467335 group (7.7% vs 7.5%, respectively). At Week 12, 5.7% (n = 2) of patients in the BI 1467335 group had a 2-step improvement in DRSS severity level from baseline, compared with 0% in the placebo group.ConclusionsBI 1467335 was well tolerated by patients with NPDR. There was a high variability in DRSS levels for individual patients over time, with no clear efficacy signal.